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Two methods for parathyroid hormone assay in serum using
commercially available reagents are compared. The Omega
Radioimmunoassay uses an antiserum with recognition for the
mid-molecular region ofparathyroid hormone (amino acid 53-68).
The Dac cell method measures both intact hormone and C-terminal
fragments.
Both assays can be completed within 24 h and offergood diagnostic
sensitivity for primary hyperparathyroidism (PHPT). The
C-terminal assay showed increased values in 85% of proven
PHPT patients compared to 96% for the mid-molecule PTH
method.
The C-terminal assayfound 73% ofhypoparathyroid patients to
have undetectable PTH levels in serum, but 54% of values in
healthy subjects were undetectable by this method.
The mid-molecule assay was clearly better in distinguishing
hypoparathyroid patients from healthy subjects, as serum PTH
was undetectable in 73% of hypoparathyroid patients and
detectable in 92% ofhealthy subjects.
Introduction
Radioimmunoassay represented a major methodological
advance in endocrinology. However, the immunohetero-
geneity of some hormones resulted in varying diagnostic
sensitivities and specificities and limited their clinical
utility. Parathyroid hormone (PTH) was one such
hormone, being rapidly metabolized in liver and kidney
[1] to yield aminoterminal (amino acid 1-34) and
carboxyl terminal (aa 35-85) and other polypeptides.
Armitage [2] in a recent review of parathyroid assay
performance listed reported studies showing that C-ter-
minal and mid-molecular assays provided clearer dis-
crimination than N-terminal assays between normal and
abnormal parathyroid function. The N-terminal assays
reflect better acute changes in parathyroid function [2
and 3].
In this report two commercial assays one with C-termi-
nal and whole hormone specificity (Dac cell) and one
with recognition for the mid-molecular region of PTH
(Omega assay) are compared, and their clinical utility
are discussed with particular reference to the prevalence
of primary hyperparathyroidism in various population
groups.
Material and methods
The commercially available PTH kits were:
(1) Dac cell PTH assay RD51 supplied by Wellcome
Diagnostics, Dartford DA 15 AH, UK.
(2) Omega PTH kit-Cambridge Medical Diagnostics
available from Biogenesis, Bucklers Way, Bourne-
mouth, UK.
Assay details relating to the antiserum characterizatioa
and tracer used, the method of standardization, phase
separation and the quality-assurance materials used are
included in table 1. The quality of packaging and
labelling of both kits is in accordance with IFCC
recommendations [4].
The assay protocol used was that supplied by the
manufacturer. Precision was assessed at two levels both
within and between batch by replicate analysis ofpooled
human serum. Other analytical techniques used were
atomic absorption spectroscopy for total calcium, ionized
calcium by ion sensitive electrode Orion SS 20 calcium
analyser.
Statistical methods
Group means were performed with the standard devia-
tion as an index of dispersion. Linear regression analysis
was performed by the method of least squares, and the
difference between means by the paired or unpaired T
test where appropriate.
Stability of PTH
Ingle et al. [5] have previously reported data showing the
stability of C-terminal PTH fragments in serum. No
significant change in PTH occurred in serum left at room
temperature for 24 h, even if not centrifuged and
separated, and no significant change in PTH was
reported after one, two or three freeze thaw cycles.
Our stability studies with the mid-molecule PTH assay
show that no marked decrease in PTH occurred when the
blood was centrifuged and the separated serum left on the
bench for 24 h at room temperature (17-21 C) (see
figure 1). When a small number of serum samples
subjected to one freeze/thaw cycle (N 6) or two
freeze/thaw cycles (N 4) were compared to the basal
value, no marked change in PTH occurred (see figure 1).
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Table 1. C-terminal (Dac cell) and mid-molecule (Omega) PTH assay details.
DAC cell assay Omega assay
Characterization
Anti-serum
Tracer
Standardization
Separation
Reference material/
PTH control
Recognizes 1"84 and C-terminal
PTH fragments
Anti-bovine PTH raised in
guinea-pig
Bovine PTH 25 labelled
to sp. act. ofapprox.
150 uCi/mg
(yellow dye incorporated)
Bovine PTH in human
Serum- conc. up to
8 tg/1 bPTH calibrated
againstMRC hPTH (1-84)
79/500
Second antibody: donkey
Recognizes 1"84 and all fragments
containing 53-68 aa sequence
Goat anti-human PTH
aa seq. 53-68
x25 labelled tyrosylated
PTH (44-68 aa seq.)
Human PTH- 1"84
0"5-15 g/1
Calibrated againstWHOhPTH
Reference preparation 79/500
Second antibody: donkey
anti-guinea-pig serum covalently Anti-goat gamma globulin
linked to cellulose
Freeze-dried human serum Processed human serum
enriched with human PTH containing synthetic human
Control serum contains PTH plus preservative
thiomeorsal as preservative
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Figure 1. PTH concentration (mid-molecule assay) in serum
separated and frozen within 1 h (basal) compared to PTH
concentration in serum stored at room temperature (17-21 C)for
24 h. Basal serum PTH concentrations are compared to PTH
levelsfollowing one freeze-thaw cycles.
Results
The precision, both within and between batch, for both
assays is shown in table 2. Between-batch precision was
similar for both assays giving CV values of 10.4% and
10"6% for the C-terminal assay and 9"4% and 10"2% for
the mid-molecule PTH assay. Recovery of added PTH
from serum gave a mean value of92"4% (range 90"9-93"3)
for the C-terminal assay, compared to a mean recovery of
92"3% (80-103"7%) for the mid molecular PTH method
(N 6). A series of replicates of the zero standard (N
20) were assayed and two standard deviations from the
mean PTH concentration was 0"13 g/1 and 0"27 tg/1 of
serum for the C-terminal and mid-molecular assays
respectively. This was the calculated minimum detect-
able amount ofPTH in serum.
A reference range was established by assay ofPTH in the
serum of apparently healthy subjects- age group 18-62
years-N 41 for the C-terminal assay and N 26 for
the mid-molecular assay. Using the C-terminal assay,
serum PTH was detectable in 19 of 41 subjects and
ranged from 0" 13 g/1 to 0"40 tg/1. Log transformation of
this data yielded a 95% range of 0"08-0"34 g/1. Serum
PTH was detectable in all but two of the 26 control
subjects. When the mid-molecular PTH assay was
performed, the mean PTH value was 0"69 ng/ml and the
95% (+ 2SD) range was 0"19-1.19 tg/1. Log trans-
formation of this data yielded a 95% range of 0"31-1"36
g/1.
Primary hyperparathyroidism (PHPT)
Serum PTH (C-terminal) in 20 patients with surgically
proven PHPT was higher than control values in all but
three cases (see figure 2). The suspected PHPT group
were hypercalcaemic patients in whom the diagnosis of
175R. Freaney et al. Performance and utility of hormone assays
Table 2. Precision ofPTH measurements using the C-terminal (Dac Cell) and mid-molecule (Omega) assays.
Within batch Between batch
C-terminal assay
Mid-molecular assay
zg/1 N CV g/1 N
%
0"32 20 8"8 0"76 20
0"46 20 10"3 2"25 20
0"90 20 12"8 1.04 20
9"50 20 4"9 7"3 20
CV
%
10.4
10"6
9"4
10"2
10,0
8,0
6,0
4,0
2,0
1.0
0.3
0.2
0.1
o
)-.:-..,-...,. :.-,.-.. .-.: ..-;..-.., .-.."
HEALTHY
SUBJECTS
!o
:: :.: .";; . DEfF 6 !iH T".".). .".;.@:."!::"
LI6NANI IDIOPATHIC
PHPT HOPT DISEASE HYPERCALCIURIA
Figure 2. Serum PTH (C-terminal assay) in healthy subjects and
patients with disorders of calcium metabolism. Primary hyper-
parathyroidism (PHPT) proven 0 suspected.
PHPT is most likely, but on whom parathyroid .surgery
has not yet been performed. In this group 20 of23 values
were higher than control subjects (see figure 2). Mid-
molecule PTH values in PHPT both proven and suspec-
ted groups showed values to be raised in 22 of23 patients.
Hypoparathyroidism (HOPT)
Eleven patients with hypoparathyroidism (surgical five,
idiopathic six) had serum PTH levels assayed by both
techniques. The C-terminal method showed that 73% of
patients were below the assay detection limit. 54% of
healthy subjects also had undetectable PTH levels by this
method.
The mid-molecule assay showed serum PTH is undetect-
able in 73% ofparathyroid subjects, but detected PTH in
the serum of92% of healthy subjects.
Hypercalcaemic malignant disease
Serum PTH values both C-terminal and mid-molecule,
measured in patients with hypercalcaemia and malignant
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Figure 3. Serum PTH (mid,molecule assay)in healthy subjects
and patients with disorders ofcalcium metabolism.
disease are shown (see figures 2 and 3 and table 3). Both
PTH assays gave some degree of overlap between
patients with PHPT and hypercalcaemic malignant
disease. This could be reduced when serum PTH was
plotted against serum calcium. Mid-molecular serum
PTH values showed clearer separation between PHPT
and hypercalcaemic malignant patients when data was
plotted in this way (see figures 4 and 5).
Idiopathic hypercalciuria (IH)
Serum PTH was measured in the serum of 10 normocal-
caemic stone-forming subjects. The C-terminal assay
failed to detect PTH in six of 10 patients and four fell
within the reference range (see figure 2). PTH values
obtained with the mid-molecule assay were not signifi-
cantly different from control values and serum PTH was
detectable in all 10 patients (see figure 3).R. Freaney et al. Performance and utility of hormone assays
Table 3. Serum calcium and PTH concentration in healthy subjects and patients with disorders ofcalcium metabolism.
Serum total Serum PTH
calcium Ionized calcium mid-molecule
Subject N mmol/1 mmol/l lg/1
Serum PTH
C-terminal
tg/1
Primary hyperparathyroid
Proven 20 2"99 _+ 0"32 1"59 _+ 0"24 4"92 (0"56-43)
Suspect 23 2"77 _+ 0" 18 1"49 + 0" 13 4"41 (0"75-25"9)
Hypoparathyroidism 11 2-01 + 0’32 1"00 +’_ 0"24 0"32 (0" 6-0-64)
Hypercalcaemic malignant disease 10 3.18 + 0"35 1.75 + 0"36 0"55 (0"20-1.48)
Idiopathic hypercalciuria 10 2"32 _+ 1"10 1"16 _+ 0"04 0"61 (0"35-1"07)
1"01 (0"14-7"43)
0"91 (0"12-7"18)
0.5 (0.09-0.)
0.21 (0.05-0.87)
0.14 (0.10-0.20)
Healthy control 2"40 + 0"07 1"20 + 0"046 0"65 (0,31-1"36) 0" 17 (0"08-0"34)
Serum calcium total and ionized are expressed as" mean SD.
Serum PTH is expressed as: mean (95% range).
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Figure 4. Serum PTH (C-terminal assay) versus serum calcium in
patients with surgically proven primary hyperparathyroidism and
malignant disease with hypercalcaemia.
Serum PTH values in all patients assayed by both
methods yielded a correlation coefficient r 0"844 (N
74). The correlation between PTH values by both
methods in the surgically proven PHPT group alone was
0"806 (N 20), and when the proven PHPT and
hypoparathyroid groups were combined (N 31) the
correlation coefficient was 0"841.
Discussion
In the past, PTH assays included antisera which
recognized either the N-terminal or C-terminal fragments
of the parathyroid hormone molecule. PTH assays using
an antiserum with mid-molecule specificity are now being
more widely used [6-10].
This comparison of C-terminal and mid-molecule PTH
assays shows that both commercial assays provide
moderately precise methods of determining PTH in
serum and both provide results within 24 h. This
177R. Freaney et al. Performance and utility of hormone assays
represents a significant improvement as many of the
previously reported in-house assays required four to six
days for completion.
Studies reported here and in a previous publication [5]
indicate the stability of both mid-molecule and C-termi-
nal fragments ofPTH in serum.
The mid-molecule PTH assay was marginally better in
the diagnosis of primary hyperparathyroidism and in
combination with serum calcium gave better separation
between PHPT and hypercalcaemic patients with malig-
nant disease. Nisbet [10], in a recent review of PTH
methodologies, also showed mid-molecule to have greater
sensitivity in primary hyperparathyroidism than intact
PTH assays, serum levels being elevated in eight of nine
cases of proven primary hyperparathyroidism. Haver et
al. [8] evaluating a radio-immunoassay kit measuring
mid-molecule PTH fragments analysed 59 patients’
specimens, 12 of which were from suspected or proven
cases of primary hyperparathyroidism. Serum PTH was
raised in 10 of 12 cases giving a sensitivity of 83%. In
distinguishing between the hypercalcaemia of malig-
.nancy and PHPT, Nisbet found the intact assay to be
more successful than the mid-molecule assay.
These studies show the mid-molecule PTH assay to be
clearly better than the C-terminal assay in the diagnosis
of hypoparathyroidism. Serum PTH values alone can
distinguish between patientswith hypoparathyroidism
and healthy subjects, with one exception. There is
considerable overlap between C-terminal PTH values in
hypoparathyroid and healthy subjects because the detec-
tion limit for PTH is not sufficiently sensitive to detect
PTH in 54% ofhealthy subjects. However, a diagnosis of
HOPT can be made when serum calcium is low and PTH
undetectable by either method.
Recent reports [11 and 12] have highlighted the increase
in hypercalcaemia discovered by biochemical screening.
This has led to a considerable increase in the number of
patients with asymptomatic PHPT. Rajathurai and
Cove-Smith [13] commenting on the prevalence and
incidence ofPHPT stated that a reliable and reproducible
test for PHPT is needed. The report shows that PTH
measurement, by either the mid-molecule or the C-termi-
nal assay, provided a useful pointer to primary hyperpa-
rathyroidism in the hypercalcaemic patient.
The prevalence ofprimary hyperparathyroidism varies in
the population studied. In the general population it is
very low one report 11 quotes a prevalence of 11 cases
per million. Assay of PTH is rarely indicated in this
situation. The presence of a clinical sign or symptom,
such as renal stone or bone pain, or the finding of a high
calcium transfers the patient to a category where the
prevalence of primary hyperparathyroidism is much
higher. The yield of positive results from PTH assay is
therefore much greater when applied in selected popula-
tions.
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TRAINING COURSE IN VISCOMETRY
The Department of Trade and Industry’s Warren Spring Laboratory is to hold a two-day training course on
viscometry on 10 to 11 February 1988. Intended for technicians and research workers who use viscometers in
their everyday work, the course will include lectures and hands-on experience on a range of instruments
available at the Laboratory. Methods of calculating data results will be included, together with viscometer
selection and the testing of difficult materials. The fee is 298.00.
Further details and a registrationform can be obtainedfrom: Ms P. Madhvi, Warren Spring Laboratory, Gunnels Wood Road,
Hertfordshire SG1 2BX, UK. Tel.: 0438 741122.
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